Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Better Communication, Better Care Using SICG Assistant Based on Artificial Intelligence (SICG-Assist)

4 agosto 2026 aggiornato da: Cudeca Hospice Foundation

Improving Care for Cancer Patients by Facilitating Communication With Clinicians Through a Serious Illness Communication Program Using an Assistant Based on Artificial Intelligence.

The project 'Better Communication, Better Care' has as its main objective to evaluate the effectiveness of the implementation of the 'Guide to conversation in serious illness (SICG)' by means of a significant reduction in anxiety and depression index in patients with serious illness and their families. Additionally, it aims to explore the perceived utility of this guide from the perspective of patients, families, and healthcare professionals involved in Palliative Care. Another important objective is to assess the effectiveness of the training program to improve communicative competencies of healthcare professionals in real clinical contexts. Furthermore, the project is structured around a pragmatic randomized clinical trial by clusters, where healthcare professionals will be randomized into intervention and control groups, with patients being the unit of analysis. In parallel, a feasibility and usability study of the mobile application and virtual assistant that will support the implementation of the guide will be conducted, evaluating parameters such as learning facility, satisfaction, efficiency, and errors through validated instruments. Finally, a cost-benefit analysis will be carried out to determine the economic efficiency of the program in terms of resource optimization and improvement in care quality.

Panoramica dello studio

Stato

Attivo, non reclutante

Intervento / Trattamento

Descrizione dettagliata

Communication is a cornerstone of person-centered care, and takes on particular importance in serious illness, defined here as a condition carrying a high risk of mortality that negatively affects quality of life or daily functioning and that commonly produces significant emotional distress in caregivers. Inadequate, delayed, or infrequent communication contributes to avoidable patient and family suffering, and clinicians often lack structured tools and training to conduct high-quality conversations about goals, values, and preferences in serious illness.

The Serious Illness Conversation Guide (SICG), originally developed and validated internationally, provides a structured framework that clinicians can use throughout the course of an illness to elicit patient values and preferences and align care accordingly. This project - conducted by a research team that collaborates directly with the guide's original international developer group - will implement the SICG in routine clinical practice across primary care and hospital-based palliative care services in the province of Málaga, Spain, supported by a purpose-built mobile application and virtual assistant designed to facilitate documentation and continuity of the conversation across multiple involved clinicians.

The study combines four complementary components:

Cluster-randomized controlled trial (quantitative, confirmatory): Healthcare professionals (HCPs) are randomized (block randomization, blocks of 4) into an intervention arm (trained in and using the SICG, supported by the app/virtual assistant) or a control arm (usual care). Patients and families are recruited by their assigned HCP and constitute the unit of analysis (multilevel/mixed-model analysis accounting for clustering at the HCP level).

Before-after evaluation of HCP communication skills and satisfaction following SICG training.

Feasibility and usability study of the mobile application and virtual assistant, using the System Usability Scale (SUS, Spanish-validated) and the mHealth App Usability Questionnaire (MAUQ).

Cost-utility analysis from the funder's perspective (1-year time horizon), estimating incremental cost-effectiveness based on training costs, implementation costs, and healthcare resource utilization (emergency and hospital admissions, palliative care referrals).

A parallel qualitative strand (individual/group narrative interviews with HCPs, patients, and family key informants) will explore perceived utility of the SICG and document emergent experiences during implementation, analyzed thematically using an iterative, constructionist approach (NVivo).

Ethical approval for evaluation of the SICG implementation has been granted by the Comité de Ética de Investigación Provincial de Málaga (session of 30/09/2021); an amendment is planned to extend approval to cover use of the supporting mobile application (feasibility study component).

Study Design Field Value Study Type Interventional Study Design Pragmatic cluster-randomized controlled trial (mixed-methods) Allocation Randomized (block randomization at HCP level, blocks of 4) Intervention Model Parallel assignment Randomization Unit Healthcare professional (cluster) Unit of Analysis Patient Masking None (open-label; not feasible to blind HCPs to guide use) Primary Purpose Supportive care / Health services research Estimated Cluster Size ~5 patients per HCP Number of Clusters 40 HCPs (20 intervention / 20 control) Condition/Disease

Serious illness (advanced/life-limiting disease with high mortality risk and significant impact on quality of life); Palliative Care

Intervention

Experimental arm: Complex two-phase intervention - (1) Training of HCPs in use of the SICG (structured communication skills course); (2) Use of the SICG by trained HCPs with patients and their families (approx. 5 patients/families per HCP), supported by a dedicated mobile application and virtual assistant.

Control arm: Standard/usual care (no SICG training or use).

Eligibility Criteria

Patients:

Serious illness as defined above Age 18-80 years Spanish as native language Karnofsky Performance Status ≥50, or ECOG Performance Status ≤2, or Palliative Performance Scale (PPS) ≥50 Signed informed consent

Family members:

Family member of an eligible patient with serious illness Age 18-80 years Spanish as native language Signed informed consent

Exclusion criteria (patients and family members): Cognitive or perceptual impairment precluding completion of study questionnaires.

Healthcare professionals (HCPs):

Inclusion: Specialists in Palliative Care, Oncology, Hematology, or Primary Care, affiliated with Fundación CUDECA, Servicio Andaluz de Salud, or Institut Català d'Oncologia Exclusion: Any professional not meeting inclusion criteria Sample Size

190 patients with serious illness, calculated to detect a between-group difference of 2.5 points in anxiety/depression scores, with 95% confidence and 80% power, accounting for a design effect of 1.2 and an intracluster correlation coefficient (ICC) of 0.05. Patients recruited via 40 HCPs, average cluster size of 5.

Outcome Measures

Primary Outcome:

Change in anxiety and depression levels (Hospital Anxiety and Depression Scale, HADS) in patients and family members, intervention vs. control group.

Secondary Outcomes:

Perceived usefulness of the SICG (patients, families, HCPs) HCP communication skills and self-efficacy (validated communication self-confidence and expected-outcomes scales; psychosocial aspects of patient care scale) SICG implementation process fidelity and reach (patient identification/referral criteria; number of eligible vs. enrolled patients) Quality of life (EuroQoL-5D-5L; QLQ-C15-PAL) Cost-utility of SICG implementation (incremental cost-effectiveness ratio) Additional patient measures: Karnofsky Index, PPS, PS, Edmonton Symptom Assessment Scale (ESAS), Distress Thermometer App/virtual assistant usability and feasibility (SUS, MAUQ; learnability, efficiency, error rate, user satisfaction, engagement) Data Collection & Analysis

Quantitative data collected via electronic case report form (REDCap, hosted by Instituto IBIMA). Qualitative data collected via audio-recorded interviews, transcribed and analyzed in NVivo. Quantitative analysis by intention-to-treat; multilevel modeling to account for clustering at the HCP level; ICC calculated for the primary outcome; repeated-measures ANOVA for within-group change over time; multivariate imputation for missing data; significance threshold p<0.05 (two-sided); SPSS v25.0.

Estimated Timeline Recruitment of HCPs and training: approx. 8 months SICG implementation and follow-up: minimum 12 months per participating HCP Utility interviews: two time points during implementation Total estimated project duration: 36 months Data Sharing / Repository

De-identified data intended for deposit in a public repository (RIUMA - Universidad de Málaga institutional repository) following FAIR principles, subject to data protection regulations (GDPR; Spanish LOPDGDD 3/2018). Minimum 10-year data availability guaranteed by the research team.

Tipo di studio

Interventistico

Iscrizione (Stimato)

190

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Málaga
      • Benalmádena, Málaga, Spagna, 29631
        • Fundación CUDECA
      • Benalmádena, Málaga, Spagna, 29631
        • CUDECA Institute/CUDECA Foundation

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Adults aged 18-80 years.
  • Diagnosis of a serious illness, defined as an illness carrying a high risk of mortality that negatively impacts quality of life or daily functioning, and that typically causes significant emotional distress in caregivers.
  • Karnofsky Performance Status ≥ 50 or Performance Status ≤ 2 or Palliative Performance Scale ≥ 50.
  • Spanish as native/fluent language, sufficient to complete the study questionnaires.
  • Cared for by an HCP enrolled in the study (intervention or control arm).
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • Cognitive or perceptual impairment that prevents reliable completion of the study questionnaires.
  • Inability to communicate in Spanish to the level required by the assessment instruments.
  • Any condition that, in the investigator's judgment, makes participation unsafe or unfeasible (e.g., clinical instability incompatible with follow-up).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Usual Care group
Usual care. the subject recieve the usual care
Sperimentale: SICG Group
The SICG Group recieved the intervention of the study. As this is a cluster trial, the intervention operates at two levels. In the case of healthcare professionals, the experimental arm receives training in the use of the SICG for subsequent use with their patients. For patients, the experimental group receives the intervention through healthcare professionals' use of the SICG to explore their wishes and expectations regarding their care.
The intervention combines a structured serious illness communication guide with an AI-powered virtual assistant app. Unlike standard communication training, the app provides real-time support during clinical encounters: it records conversations automatically, suggests unexplored topics to the clinician, and enables post-visit discourse analysis to anticipate patient needs and predict clinical events. Healthcare professionals receive training in the use of the guide and app. Effectiveness is evaluated through a pragmatic cluster-randomized controlled trial (unit of randomization: HCP; unit of analysis: patient), a before-after design assessing HCP communication skills and satisfaction, a feasibility study using SUS and MAUQ questionnaires, and a cost-utility analysis over a one-year horizon. Qualitative data are collected via narrative interviews with HCPs and patient/family key informants to capture implementation experiences and emergent causal pathways.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in patient anxiety and depression
Lasso di tempo: Baseline, 1 month, 3 months, and 6 months after SICG conversation (or equivalent index visit in the control arm).
Change from baseline in Hospital Anxiety and Depression Scale (HADS) score in patients with serious illness, comparing intervention arm (care delivered by HCPs trained in the Serious Illness Conversation Guide [SICG]) vs. control arm (standard care). HADS comprises 14 items (7 anxiety, 7 depression), each scored 0-3; subscale range 0-21. Higher scores indicate worse symptoms. A between-group difference of 2.5 points is considered clinically relevant.
Baseline, 1 month, 3 months, and 6 months after SICG conversation (or equivalent index visit in the control arm).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in family-caregiver anxiety and depression
Lasso di tempo: Baseline, 3 months, and 6 months after the patient's SICG conversation.
Change from baseline in HADS score among family caregivers of enrolled patients. Same scoring as above (range 0-21 per subscale; higher = worse).
Baseline, 3 months, and 6 months after the patient's SICG conversation.
Patient health-related quality of life (EuroQoL-5D-5L)
Lasso di tempo: Baseline, 3 months, and 6 months.
Change in EQ-5D-5L index value (utility score, range -0.594 to 1.000; higher = better QoL) and EQ-VAS (0-100). Used both as a clinical outcome and as the utility metric for the cost-utility analysis (QALYs).
Baseline, 3 months, and 6 months.
Patient cancer-specific quality of life (EORTC QLQ-C15-PAL)
Lasso di tempo: Baseline, 3 months, and 6 months.
Change in QLQ-C15-PAL, the 15-item palliative-care short form of the QLQ-C30. Functional and symptom subscales linearly transformed to 0-100.
Baseline, 3 months, and 6 months.
Family-caregiver health-related quality of life (EuroQoL-5D-5L)
Lasso di tempo: Baseline, 3 months, and 6 months.
Change in EQ-5D-5L index and EQ-VAS in family caregivers.
Baseline, 3 months, and 6 months.
Patient symptom burden (ESAS)
Lasso di tempo: Baseline, 1 month, 3 months, and 6 months.
Change in Edmonton Symptom Assessment System total distress score (10 symptoms, each 0-10; total 0-100; higher = worse).
Baseline, 1 month, 3 months, and 6 months.
Patient and caregiver distress (Distress Thermometer)
Lasso di tempo: Baseline, 1 month, 3 months, and 6 months.
Change in NCCN Distress Thermometer score (single-item visual analogue, 0-10; ≥4 = clinically significant distress).
Baseline, 1 month, 3 months, and 6 months.
Patient functional status (Karnofsky Performance Status / Palliative Performance Scale)
Lasso di tempo: Baseline, 3 months, and 6 months.
Change in Karnofsky Performance Status (0-100, higher = better function) and Palliative Performance Scale (0-100% in 10% decrements). Used both as descriptive variables and as eligibility-confirmation measures (KPS ≥50 or PPS ≥50 at enrolment).
Baseline, 3 months, and 6 months.
Patient and family satisfaction with SICG
Lasso di tempo: Within 2 weeks after the SICG conversation.
Ad-hoc satisfaction questionnaire on the use and perceived helpfulness of the Serious Illness Conversation, administered after the index conversation. more satisfaction better care.
Within 2 weeks after the SICG conversation.
HCP communication self-efficacy and attitudes (pre-post training)
Lasso di tempo: Baseline (pre-training), immediately post-training, and 6 and 12 months after training.
Change in three validated scales administered to participating healthcare professionals: (a) Self-Efficacy in Communication Skills scale; (b) Expected Outcomes of Communication scale; (c) Psychosocial Aspects of Patient Care scale. Higher scores indicate greater confidence, more positive expectations, and greater attention to psychosocial care, respectively.
Baseline (pre-training), immediately post-training, and 6 and 12 months after training.
HCP satisfaction with SICP training and implementation
Lasso di tempo: Immediately after training and 12 months after the start of SICG implementation.
Ad-hoc satisfaction questionnaire on the SICP training programme and on the experience of implementing the SICG in routine practice. Better score better satisfaction.
Immediately after training and 12 months after the start of SICG implementation.
Healthcare resource utilization
Lasso di tempo: From index conversation through 6 months of follow-up.
Number and type of contacts with healthcare services during the 6 months following the index conversation, extracted from electronic health records: emergency-department visits, hospital admissions and length of stay, outpatient visits, and referrals to specialist palliative care.
From index conversation through 6 months of follow-up.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 gennaio 2026

Completamento primario (Stimato)

31 ottobre 2028

Completamento dello studio (Stimato)

31 dicembre 2028

Date di iscrizione allo studio

Primo inviato

27 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

4 agosto 2026

Primo Inserito (Effettivo)

7 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

7 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 agosto 2026

Ultimo verificato

1 aprile 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi